February 20, 2020
Kowa said on February 19 that it has started a PIII clinical study of fixed-dose combination eye drops containing its Rho kinase inhibitor Glanatec (ripasudil) and brimonidine tartrate for glaucoma and ocular hypertension in Japan. Glanatec hit the Japan market...read more